nodes	percent_of_prediction	percent_of_DWPC	metapath
Hyoscyamine—Urticaria—Prednisolone—hematologic cancer	0.000112	0.00013	CcSEcCtD
Hyoscyamine—Asthenia—Cisplatin—hematologic cancer	0.000112	0.000129	CcSEcCtD
Hyoscyamine—Fatigue—Triamcinolone—hematologic cancer	0.000112	0.000129	CcSEcCtD
Hyoscyamine—Sweating—Doxorubicin—hematologic cancer	0.000111	0.000129	CcSEcCtD
Hyoscyamine—Rash—Vincristine—hematologic cancer	0.000111	0.000129	CcSEcCtD
Hyoscyamine—Dermatitis—Vincristine—hematologic cancer	0.000111	0.000129	CcSEcCtD
Hyoscyamine—Pain—Triamcinolone—hematologic cancer	0.000111	0.000128	CcSEcCtD
Hyoscyamine—Headache—Vincristine—hematologic cancer	0.00011	0.000128	CcSEcCtD
Hyoscyamine—Loss of consciousness—Prednisone—hematologic cancer	0.00011	0.000128	CcSEcCtD
Hyoscyamine—Hypotension—Dexamethasone—hematologic cancer	0.00011	0.000127	CcSEcCtD
Hyoscyamine—Hypotension—Betamethasone—hematologic cancer	0.00011	0.000127	CcSEcCtD
Hyoscyamine—Nausea—Carmustine—hematologic cancer	0.00011	0.000127	CcSEcCtD
Hyoscyamine—Vomiting—Irinotecan—hematologic cancer	0.000109	0.000126	CcSEcCtD
Hyoscyamine—Vomiting—Mitoxantrone—hematologic cancer	0.000109	0.000126	CcSEcCtD
Hyoscyamine—Nausea—Alitretinoin—hematologic cancer	0.000109	0.000126	CcSEcCtD
Hyoscyamine—Convulsion—Prednisone—hematologic cancer	0.000109	0.000126	CcSEcCtD
Hyoscyamine—Rash—Mitoxantrone—hematologic cancer	0.000108	0.000125	CcSEcCtD
Hyoscyamine—Rash—Irinotecan—hematologic cancer	0.000108	0.000125	CcSEcCtD
Hyoscyamine—Dermatitis—Mitoxantrone—hematologic cancer	0.000108	0.000125	CcSEcCtD
Hyoscyamine—Dermatitis—Irinotecan—hematologic cancer	0.000108	0.000125	CcSEcCtD
Hyoscyamine—Headache—Mitoxantrone—hematologic cancer	0.000107	0.000124	CcSEcCtD
Hyoscyamine—Headache—Irinotecan—hematologic cancer	0.000107	0.000124	CcSEcCtD
Hyoscyamine—Nausea—Ifosfamide—hematologic cancer	0.000107	0.000124	CcSEcCtD
Hyoscyamine—Feeling abnormal—Triamcinolone—hematologic cancer	0.000107	0.000124	CcSEcCtD
Hyoscyamine—Diarrhoea—Cisplatin—hematologic cancer	0.000107	0.000123	CcSEcCtD
Hyoscyamine—Anxiety—Prednisone—hematologic cancer	0.000106	0.000123	CcSEcCtD
Hyoscyamine—Vomiting—Gemcitabine—hematologic cancer	0.000106	0.000123	CcSEcCtD
Hyoscyamine—Insomnia—Dexamethasone—hematologic cancer	0.000106	0.000123	CcSEcCtD
Hyoscyamine—Insomnia—Betamethasone—hematologic cancer	0.000106	0.000123	CcSEcCtD
Hyoscyamine—Bradycardia—Doxorubicin—hematologic cancer	0.000106	0.000123	CcSEcCtD
Hyoscyamine—Mental disorder—Methotrexate—hematologic cancer	0.000105	0.000122	CcSEcCtD
Hyoscyamine—Rash—Gemcitabine—hematologic cancer	0.000105	0.000122	CcSEcCtD
Hyoscyamine—Dermatitis—Gemcitabine—hematologic cancer	0.000105	0.000122	CcSEcCtD
Hyoscyamine—Hypersensitivity—Etoposide—hematologic cancer	0.000105	0.000122	CcSEcCtD
Hyoscyamine—Erythema—Methotrexate—hematologic cancer	0.000105	0.000121	CcSEcCtD
Hyoscyamine—Headache—Gemcitabine—hematologic cancer	0.000105	0.000121	CcSEcCtD
Hyoscyamine—Nausea—Vincristine—hematologic cancer	0.000105	0.000121	CcSEcCtD
Hyoscyamine—Flushing—Epirubicin—hematologic cancer	0.000104	0.000121	CcSEcCtD
Hyoscyamine—Hypersensitivity—Prednisolone—hematologic cancer	0.000104	0.00012	CcSEcCtD
Hyoscyamine—Dyspepsia—Betamethasone—hematologic cancer	0.000103	0.00012	CcSEcCtD
Hyoscyamine—Dyspepsia—Dexamethasone—hematologic cancer	0.000103	0.00012	CcSEcCtD
Hyoscyamine—Urticaria—Triamcinolone—hematologic cancer	0.000103	0.000119	CcSEcCtD
Hyoscyamine—Dysgeusia—Methotrexate—hematologic cancer	0.000103	0.000119	CcSEcCtD
Hyoscyamine—Asthenia—Etoposide—hematologic cancer	0.000102	0.000119	CcSEcCtD
Hyoscyamine—Body temperature increased—Triamcinolone—hematologic cancer	0.000102	0.000119	CcSEcCtD
Hyoscyamine—Oedema—Prednisone—hematologic cancer	0.000102	0.000118	CcSEcCtD
Hyoscyamine—Anaphylactic shock—Prednisone—hematologic cancer	0.000102	0.000118	CcSEcCtD
Hyoscyamine—Nausea—Mitoxantrone—hematologic cancer	0.000102	0.000118	CcSEcCtD
Hyoscyamine—Nausea—Irinotecan—hematologic cancer	0.000102	0.000118	CcSEcCtD
Hyoscyamine—Fatigue—Betamethasone—hematologic cancer	0.000101	0.000117	CcSEcCtD
Hyoscyamine—Fatigue—Dexamethasone—hematologic cancer	0.000101	0.000117	CcSEcCtD
Hyoscyamine—Pruritus—Etoposide—hematologic cancer	0.000101	0.000117	CcSEcCtD
Hyoscyamine—Shock—Prednisone—hematologic cancer	0.000101	0.000117	CcSEcCtD
Hyoscyamine—Arrhythmia—Epirubicin—hematologic cancer	0.000101	0.000117	CcSEcCtD
Hyoscyamine—Pain—Betamethasone—hematologic cancer	0.0001	0.000116	CcSEcCtD
Hyoscyamine—Pain—Dexamethasone—hematologic cancer	0.0001	0.000116	CcSEcCtD
Hyoscyamine—Tachycardia—Prednisone—hematologic cancer	9.98e-05	0.000116	CcSEcCtD
Hyoscyamine—Nausea—Gemcitabine—hematologic cancer	9.92e-05	0.000115	CcSEcCtD
Hyoscyamine—Vomiting—Cisplatin—hematologic cancer	9.9e-05	0.000115	CcSEcCtD
Hyoscyamine—Hyperhidrosis—Prednisone—hematologic cancer	9.88e-05	0.000115	CcSEcCtD
Hyoscyamine—Vision blurred—Methotrexate—hematologic cancer	9.87e-05	0.000114	CcSEcCtD
Hyoscyamine—Mental disorder—Epirubicin—hematologic cancer	9.86e-05	0.000114	CcSEcCtD
Hyoscyamine—Rash—Cisplatin—hematologic cancer	9.82e-05	0.000114	CcSEcCtD
Hyoscyamine—Dermatitis—Cisplatin—hematologic cancer	9.81e-05	0.000114	CcSEcCtD
Hyoscyamine—Erythema—Epirubicin—hematologic cancer	9.8e-05	0.000114	CcSEcCtD
Hyoscyamine—Diarrhoea—Etoposide—hematologic cancer	9.76e-05	0.000113	CcSEcCtD
Hyoscyamine—Feeling abnormal—Dexamethasone—hematologic cancer	9.67e-05	0.000112	CcSEcCtD
Hyoscyamine—Feeling abnormal—Betamethasone—hematologic cancer	9.67e-05	0.000112	CcSEcCtD
Hyoscyamine—Flushing—Doxorubicin—hematologic cancer	9.66e-05	0.000112	CcSEcCtD
Hyoscyamine—Tension—Epirubicin—hematologic cancer	9.61e-05	0.000111	CcSEcCtD
Hyoscyamine—Gastrointestinal pain—Betamethasone—hematologic cancer	9.6e-05	0.000111	CcSEcCtD
Hyoscyamine—Gastrointestinal pain—Dexamethasone—hematologic cancer	9.6e-05	0.000111	CcSEcCtD
Hyoscyamine—Dysgeusia—Epirubicin—hematologic cancer	9.59e-05	0.000111	CcSEcCtD
Hyoscyamine—Hypersensitivity—Triamcinolone—hematologic cancer	9.53e-05	0.00011	CcSEcCtD
Hyoscyamine—Nervousness—Epirubicin—hematologic cancer	9.52e-05	0.00011	CcSEcCtD
Hyoscyamine—Dizziness—Etoposide—hematologic cancer	9.43e-05	0.000109	CcSEcCtD
Hyoscyamine—Vertigo—Methotrexate—hematologic cancer	9.41e-05	0.000109	CcSEcCtD
Hyoscyamine—Urticaria—Betamethasone—hematologic cancer	9.33e-05	0.000108	CcSEcCtD
Hyoscyamine—Urticaria—Dexamethasone—hematologic cancer	9.33e-05	0.000108	CcSEcCtD
Hyoscyamine—Dizziness—Prednisolone—hematologic cancer	9.3e-05	0.000108	CcSEcCtD
Hyoscyamine—Arrhythmia—Doxorubicin—hematologic cancer	9.3e-05	0.000108	CcSEcCtD
Hyoscyamine—Asthenia—Triamcinolone—hematologic cancer	9.28e-05	0.000108	CcSEcCtD
Hyoscyamine—Abdominal pain—Betamethasone—hematologic cancer	9.28e-05	0.000108	CcSEcCtD
Hyoscyamine—Body temperature increased—Betamethasone—hematologic cancer	9.28e-05	0.000108	CcSEcCtD
Hyoscyamine—Body temperature increased—Dexamethasone—hematologic cancer	9.28e-05	0.000108	CcSEcCtD
Hyoscyamine—Abdominal pain—Dexamethasone—hematologic cancer	9.28e-05	0.000108	CcSEcCtD
Hyoscyamine—Nausea—Cisplatin—hematologic cancer	9.25e-05	0.000107	CcSEcCtD
Hyoscyamine—Insomnia—Prednisone—hematologic cancer	9.25e-05	0.000107	CcSEcCtD
Hyoscyamine—Vision blurred—Epirubicin—hematologic cancer	9.23e-05	0.000107	CcSEcCtD
Hyoscyamine—Pruritus—Triamcinolone—hematologic cancer	9.15e-05	0.000106	CcSEcCtD
Hyoscyamine—Mental disorder—Doxorubicin—hematologic cancer	9.12e-05	0.000106	CcSEcCtD
Hyoscyamine—Convulsion—Methotrexate—hematologic cancer	9.07e-05	0.000105	CcSEcCtD
Hyoscyamine—Vomiting—Etoposide—hematologic cancer	9.07e-05	0.000105	CcSEcCtD
Hyoscyamine—Erythema—Doxorubicin—hematologic cancer	9.07e-05	0.000105	CcSEcCtD
Hyoscyamine—Agitation—Epirubicin—hematologic cancer	9e-05	0.000104	CcSEcCtD
Hyoscyamine—Dyspepsia—Prednisone—hematologic cancer	9e-05	0.000104	CcSEcCtD
Hyoscyamine—Rash—Etoposide—hematologic cancer	8.99e-05	0.000104	CcSEcCtD
Hyoscyamine—Dermatitis—Etoposide—hematologic cancer	8.99e-05	0.000104	CcSEcCtD
Hyoscyamine—Headache—Etoposide—hematologic cancer	8.94e-05	0.000104	CcSEcCtD
Hyoscyamine—Chest pain—Methotrexate—hematologic cancer	8.91e-05	0.000103	CcSEcCtD
Hyoscyamine—Tension—Doxorubicin—hematologic cancer	8.9e-05	0.000103	CcSEcCtD
Hyoscyamine—Dysgeusia—Doxorubicin—hematologic cancer	8.88e-05	0.000103	CcSEcCtD
Hyoscyamine—Rash—Prednisolone—hematologic cancer	8.87e-05	0.000103	CcSEcCtD
Hyoscyamine—Dermatitis—Prednisolone—hematologic cancer	8.86e-05	0.000103	CcSEcCtD
Hyoscyamine—Fatigue—Prednisone—hematologic cancer	8.81e-05	0.000102	CcSEcCtD
Hyoscyamine—Headache—Prednisolone—hematologic cancer	8.81e-05	0.000102	CcSEcCtD
Hyoscyamine—Nervousness—Doxorubicin—hematologic cancer	8.8e-05	0.000102	CcSEcCtD
Hyoscyamine—Vertigo—Epirubicin—hematologic cancer	8.8e-05	0.000102	CcSEcCtD
Hyoscyamine—Syncope—Epirubicin—hematologic cancer	8.79e-05	0.000102	CcSEcCtD
Hyoscyamine—Constipation—Prednisone—hematologic cancer	8.74e-05	0.000101	CcSEcCtD
Hyoscyamine—Palpitations—Epirubicin—hematologic cancer	8.66e-05	0.0001	CcSEcCtD
Hyoscyamine—Confusional state—Methotrexate—hematologic cancer	8.62e-05	9.98e-05	CcSEcCtD
Hyoscyamine—Loss of consciousness—Epirubicin—hematologic cancer	8.61e-05	9.98e-05	CcSEcCtD
Hyoscyamine—Dizziness—Triamcinolone—hematologic cancer	8.56e-05	9.91e-05	CcSEcCtD
Hyoscyamine—Anaphylactic shock—Methotrexate—hematologic cancer	8.54e-05	9.9e-05	CcSEcCtD
Hyoscyamine—Vision blurred—Doxorubicin—hematologic cancer	8.54e-05	9.9e-05	CcSEcCtD
Hyoscyamine—Convulsion—Epirubicin—hematologic cancer	8.49e-05	9.84e-05	CcSEcCtD
Hyoscyamine—Nausea—Etoposide—hematologic cancer	8.47e-05	9.82e-05	CcSEcCtD
Hyoscyamine—Feeling abnormal—Prednisone—hematologic cancer	8.42e-05	9.76e-05	CcSEcCtD
Hyoscyamine—Asthenia—Betamethasone—hematologic cancer	8.42e-05	9.76e-05	CcSEcCtD
Hyoscyamine—Asthenia—Dexamethasone—hematologic cancer	8.42e-05	9.76e-05	CcSEcCtD
Hyoscyamine—Gastrointestinal pain—Prednisone—hematologic cancer	8.36e-05	9.69e-05	CcSEcCtD
Hyoscyamine—Nausea—Prednisolone—hematologic cancer	8.36e-05	9.68e-05	CcSEcCtD
Hyoscyamine—Chest pain—Epirubicin—hematologic cancer	8.34e-05	9.67e-05	CcSEcCtD
Hyoscyamine—Agitation—Doxorubicin—hematologic cancer	8.33e-05	9.65e-05	CcSEcCtD
Hyoscyamine—Anxiety—Epirubicin—hematologic cancer	8.31e-05	9.63e-05	CcSEcCtD
Hyoscyamine—Pruritus—Dexamethasone—hematologic cancer	8.31e-05	9.62e-05	CcSEcCtD
Hyoscyamine—Pruritus—Betamethasone—hematologic cancer	8.31e-05	9.62e-05	CcSEcCtD
Hyoscyamine—Hyperhidrosis—Methotrexate—hematologic cancer	8.26e-05	9.57e-05	CcSEcCtD
Hyoscyamine—Vomiting—Triamcinolone—hematologic cancer	8.23e-05	9.53e-05	CcSEcCtD
Hyoscyamine—Rash—Triamcinolone—hematologic cancer	8.16e-05	9.45e-05	CcSEcCtD
Hyoscyamine—Dry mouth—Epirubicin—hematologic cancer	8.16e-05	9.45e-05	CcSEcCtD
Hyoscyamine—Dermatitis—Triamcinolone—hematologic cancer	8.15e-05	9.44e-05	CcSEcCtD
Hyoscyamine—Vertigo—Doxorubicin—hematologic cancer	8.14e-05	9.44e-05	CcSEcCtD
Hyoscyamine—Syncope—Doxorubicin—hematologic cancer	8.13e-05	9.42e-05	CcSEcCtD
Hyoscyamine—Urticaria—Prednisone—hematologic cancer	8.12e-05	9.41e-05	CcSEcCtD
Hyoscyamine—Headache—Triamcinolone—hematologic cancer	8.11e-05	9.39e-05	CcSEcCtD
Hyoscyamine—Body temperature increased—Prednisone—hematologic cancer	8.08e-05	9.37e-05	CcSEcCtD
Hyoscyamine—Abdominal pain—Prednisone—hematologic cancer	8.08e-05	9.37e-05	CcSEcCtD
Hyoscyamine—Confusional state—Epirubicin—hematologic cancer	8.06e-05	9.34e-05	CcSEcCtD
Hyoscyamine—Diarrhoea—Dexamethasone—hematologic cancer	8.03e-05	9.31e-05	CcSEcCtD
Hyoscyamine—Diarrhoea—Betamethasone—hematologic cancer	8.03e-05	9.31e-05	CcSEcCtD
Hyoscyamine—Palpitations—Doxorubicin—hematologic cancer	8.01e-05	9.28e-05	CcSEcCtD
Hyoscyamine—Oedema—Epirubicin—hematologic cancer	8e-05	9.27e-05	CcSEcCtD
Hyoscyamine—Anaphylactic shock—Epirubicin—hematologic cancer	8e-05	9.27e-05	CcSEcCtD
Hyoscyamine—Hypotension—Methotrexate—hematologic cancer	7.98e-05	9.25e-05	CcSEcCtD
Hyoscyamine—Loss of consciousness—Doxorubicin—hematologic cancer	7.97e-05	9.23e-05	CcSEcCtD
Hyoscyamine—Shock—Epirubicin—hematologic cancer	7.87e-05	9.12e-05	CcSEcCtD
Hyoscyamine—Convulsion—Doxorubicin—hematologic cancer	7.85e-05	9.1e-05	CcSEcCtD
Hyoscyamine—Tachycardia—Epirubicin—hematologic cancer	7.8e-05	9.04e-05	CcSEcCtD
Hyoscyamine—Dizziness—Betamethasone—hematologic cancer	7.76e-05	9e-05	CcSEcCtD
Hyoscyamine—Dizziness—Dexamethasone—hematologic cancer	7.76e-05	9e-05	CcSEcCtD
Hyoscyamine—Hyperhidrosis—Epirubicin—hematologic cancer	7.73e-05	8.96e-05	CcSEcCtD
Hyoscyamine—Insomnia—Methotrexate—hematologic cancer	7.73e-05	8.95e-05	CcSEcCtD
Hyoscyamine—Chest pain—Doxorubicin—hematologic cancer	7.72e-05	8.94e-05	CcSEcCtD
Hyoscyamine—Anxiety—Doxorubicin—hematologic cancer	7.69e-05	8.91e-05	CcSEcCtD
Hyoscyamine—Nausea—Triamcinolone—hematologic cancer	7.69e-05	8.91e-05	CcSEcCtD
Hyoscyamine—Dyspnoea—Methotrexate—hematologic cancer	7.62e-05	8.83e-05	CcSEcCtD
Hyoscyamine—Somnolence—Methotrexate—hematologic cancer	7.6e-05	8.8e-05	CcSEcCtD
Hyoscyamine—Dry mouth—Doxorubicin—hematologic cancer	7.55e-05	8.75e-05	CcSEcCtD
Hyoscyamine—Hypersensitivity—Prednisone—hematologic cancer	7.53e-05	8.73e-05	CcSEcCtD
Hyoscyamine—Dyspepsia—Methotrexate—hematologic cancer	7.52e-05	8.72e-05	CcSEcCtD
Hyoscyamine—Hypotension—Epirubicin—hematologic cancer	7.47e-05	8.66e-05	CcSEcCtD
Hyoscyamine—Vomiting—Betamethasone—hematologic cancer	7.46e-05	8.65e-05	CcSEcCtD
Hyoscyamine—Vomiting—Dexamethasone—hematologic cancer	7.46e-05	8.65e-05	CcSEcCtD
Hyoscyamine—Confusional state—Doxorubicin—hematologic cancer	7.46e-05	8.64e-05	CcSEcCtD
Hyoscyamine—Rash—Dexamethasone—hematologic cancer	7.4e-05	8.58e-05	CcSEcCtD
Hyoscyamine—Rash—Betamethasone—hematologic cancer	7.4e-05	8.58e-05	CcSEcCtD
Hyoscyamine—Oedema—Doxorubicin—hematologic cancer	7.4e-05	8.57e-05	CcSEcCtD
Hyoscyamine—Anaphylactic shock—Doxorubicin—hematologic cancer	7.4e-05	8.57e-05	CcSEcCtD
Hyoscyamine—Dermatitis—Dexamethasone—hematologic cancer	7.4e-05	8.57e-05	CcSEcCtD
Hyoscyamine—Dermatitis—Betamethasone—hematologic cancer	7.4e-05	8.57e-05	CcSEcCtD
Hyoscyamine—Fatigue—Methotrexate—hematologic cancer	7.37e-05	8.54e-05	CcSEcCtD
Hyoscyamine—Headache—Dexamethasone—hematologic cancer	7.35e-05	8.52e-05	CcSEcCtD
Hyoscyamine—Headache—Betamethasone—hematologic cancer	7.35e-05	8.52e-05	CcSEcCtD
Hyoscyamine—Asthenia—Prednisone—hematologic cancer	7.34e-05	8.5e-05	CcSEcCtD
Hyoscyamine—Pain—Methotrexate—hematologic cancer	7.31e-05	8.47e-05	CcSEcCtD
Hyoscyamine—Shock—Doxorubicin—hematologic cancer	7.28e-05	8.43e-05	CcSEcCtD
Hyoscyamine—Pruritus—Prednisone—hematologic cancer	7.23e-05	8.38e-05	CcSEcCtD
Hyoscyamine—Insomnia—Epirubicin—hematologic cancer	7.23e-05	8.38e-05	CcSEcCtD
Hyoscyamine—Tachycardia—Doxorubicin—hematologic cancer	7.22e-05	8.37e-05	CcSEcCtD
Hyoscyamine—Hyperhidrosis—Doxorubicin—hematologic cancer	7.15e-05	8.29e-05	CcSEcCtD
Hyoscyamine—Dyspnoea—Epirubicin—hematologic cancer	7.13e-05	8.26e-05	CcSEcCtD
Hyoscyamine—Somnolence—Epirubicin—hematologic cancer	7.11e-05	8.24e-05	CcSEcCtD
Hyoscyamine—Feeling abnormal—Methotrexate—hematologic cancer	7.04e-05	8.16e-05	CcSEcCtD
Hyoscyamine—Dyspepsia—Epirubicin—hematologic cancer	7.04e-05	8.16e-05	CcSEcCtD
Hyoscyamine—Diarrhoea—Prednisone—hematologic cancer	7e-05	8.11e-05	CcSEcCtD
Hyoscyamine—Gastrointestinal pain—Methotrexate—hematologic cancer	6.99e-05	8.1e-05	CcSEcCtD
Hyoscyamine—Nausea—Dexamethasone—hematologic cancer	6.97e-05	8.08e-05	CcSEcCtD
Hyoscyamine—Nausea—Betamethasone—hematologic cancer	6.97e-05	8.08e-05	CcSEcCtD
Hyoscyamine—Hypotension—Doxorubicin—hematologic cancer	6.91e-05	8.01e-05	CcSEcCtD
Hyoscyamine—Fatigue—Epirubicin—hematologic cancer	6.89e-05	7.99e-05	CcSEcCtD
Hyoscyamine—Constipation—Epirubicin—hematologic cancer	6.84e-05	7.92e-05	CcSEcCtD
Hyoscyamine—Pain—Epirubicin—hematologic cancer	6.84e-05	7.92e-05	CcSEcCtD
Hyoscyamine—Urticaria—Methotrexate—hematologic cancer	6.79e-05	7.87e-05	CcSEcCtD
Hyoscyamine—Dizziness—Prednisone—hematologic cancer	6.76e-05	7.83e-05	CcSEcCtD
Hyoscyamine—Abdominal pain—Methotrexate—hematologic cancer	6.75e-05	7.83e-05	CcSEcCtD
Hyoscyamine—Body temperature increased—Methotrexate—hematologic cancer	6.75e-05	7.83e-05	CcSEcCtD
Hyoscyamine—Insomnia—Doxorubicin—hematologic cancer	6.69e-05	7.75e-05	CcSEcCtD
Hyoscyamine—Dyspnoea—Doxorubicin—hematologic cancer	6.6e-05	7.64e-05	CcSEcCtD
Hyoscyamine—Feeling abnormal—Epirubicin—hematologic cancer	6.59e-05	7.64e-05	CcSEcCtD
Hyoscyamine—Somnolence—Doxorubicin—hematologic cancer	6.58e-05	7.62e-05	CcSEcCtD
Hyoscyamine—Gastrointestinal pain—Epirubicin—hematologic cancer	6.54e-05	7.58e-05	CcSEcCtD
Hyoscyamine—Dyspepsia—Doxorubicin—hematologic cancer	6.51e-05	7.55e-05	CcSEcCtD
Hyoscyamine—Vomiting—Prednisone—hematologic cancer	6.5e-05	7.53e-05	CcSEcCtD
Hyoscyamine—Rash—Prednisone—hematologic cancer	6.45e-05	7.47e-05	CcSEcCtD
Hyoscyamine—Dermatitis—Prednisone—hematologic cancer	6.44e-05	7.46e-05	CcSEcCtD
Hyoscyamine—Headache—Prednisone—hematologic cancer	6.4e-05	7.42e-05	CcSEcCtD
Hyoscyamine—Fatigue—Doxorubicin—hematologic cancer	6.38e-05	7.39e-05	CcSEcCtD
Hyoscyamine—Urticaria—Epirubicin—hematologic cancer	6.35e-05	7.36e-05	CcSEcCtD
Hyoscyamine—Pain—Doxorubicin—hematologic cancer	6.33e-05	7.33e-05	CcSEcCtD
Hyoscyamine—Constipation—Doxorubicin—hematologic cancer	6.33e-05	7.33e-05	CcSEcCtD
Hyoscyamine—Abdominal pain—Epirubicin—hematologic cancer	6.32e-05	7.32e-05	CcSEcCtD
Hyoscyamine—Body temperature increased—Epirubicin—hematologic cancer	6.32e-05	7.32e-05	CcSEcCtD
Hyoscyamine—Hypersensitivity—Methotrexate—hematologic cancer	6.3e-05	7.29e-05	CcSEcCtD
Hyoscyamine—Asthenia—Methotrexate—hematologic cancer	6.13e-05	7.1e-05	CcSEcCtD
Hyoscyamine—Feeling abnormal—Doxorubicin—hematologic cancer	6.1e-05	7.06e-05	CcSEcCtD
Hyoscyamine—Nausea—Prednisone—hematologic cancer	6.07e-05	7.04e-05	CcSEcCtD
Hyoscyamine—Gastrointestinal pain—Doxorubicin—hematologic cancer	6.05e-05	7.01e-05	CcSEcCtD
Hyoscyamine—Pruritus—Methotrexate—hematologic cancer	6.04e-05	7e-05	CcSEcCtD
Hyoscyamine—Hypersensitivity—Epirubicin—hematologic cancer	5.89e-05	6.83e-05	CcSEcCtD
Hyoscyamine—Urticaria—Doxorubicin—hematologic cancer	5.88e-05	6.81e-05	CcSEcCtD
Hyoscyamine—Abdominal pain—Doxorubicin—hematologic cancer	5.85e-05	6.78e-05	CcSEcCtD
Hyoscyamine—Body temperature increased—Doxorubicin—hematologic cancer	5.85e-05	6.78e-05	CcSEcCtD
Hyoscyamine—Diarrhoea—Methotrexate—hematologic cancer	5.85e-05	6.77e-05	CcSEcCtD
Hyoscyamine—Asthenia—Epirubicin—hematologic cancer	5.74e-05	6.65e-05	CcSEcCtD
Hyoscyamine—Pruritus—Epirubicin—hematologic cancer	5.66e-05	6.56e-05	CcSEcCtD
Hyoscyamine—Dizziness—Methotrexate—hematologic cancer	5.65e-05	6.55e-05	CcSEcCtD
Hyoscyamine—Diarrhoea—Epirubicin—hematologic cancer	5.47e-05	6.34e-05	CcSEcCtD
Hyoscyamine—Hypersensitivity—Doxorubicin—hematologic cancer	5.45e-05	6.32e-05	CcSEcCtD
Hyoscyamine—Vomiting—Methotrexate—hematologic cancer	5.43e-05	6.3e-05	CcSEcCtD
Hyoscyamine—Rash—Methotrexate—hematologic cancer	5.39e-05	6.24e-05	CcSEcCtD
Hyoscyamine—Dermatitis—Methotrexate—hematologic cancer	5.38e-05	6.24e-05	CcSEcCtD
Hyoscyamine—Headache—Methotrexate—hematologic cancer	5.35e-05	6.2e-05	CcSEcCtD
Hyoscyamine—Asthenia—Doxorubicin—hematologic cancer	5.31e-05	6.15e-05	CcSEcCtD
Hyoscyamine—Dizziness—Epirubicin—hematologic cancer	5.29e-05	6.13e-05	CcSEcCtD
Hyoscyamine—Pruritus—Doxorubicin—hematologic cancer	5.23e-05	6.07e-05	CcSEcCtD
Hyoscyamine—Vomiting—Epirubicin—hematologic cancer	5.08e-05	5.89e-05	CcSEcCtD
Hyoscyamine—Nausea—Methotrexate—hematologic cancer	5.08e-05	5.88e-05	CcSEcCtD
Hyoscyamine—Diarrhoea—Doxorubicin—hematologic cancer	5.06e-05	5.87e-05	CcSEcCtD
Hyoscyamine—Rash—Epirubicin—hematologic cancer	5.04e-05	5.84e-05	CcSEcCtD
Hyoscyamine—Dermatitis—Epirubicin—hematologic cancer	5.04e-05	5.84e-05	CcSEcCtD
Hyoscyamine—Headache—Epirubicin—hematologic cancer	5.01e-05	5.8e-05	CcSEcCtD
Hyoscyamine—Dizziness—Doxorubicin—hematologic cancer	4.89e-05	5.67e-05	CcSEcCtD
Hyoscyamine—Nausea—Epirubicin—hematologic cancer	4.75e-05	5.5e-05	CcSEcCtD
Hyoscyamine—Vomiting—Doxorubicin—hematologic cancer	4.7e-05	5.45e-05	CcSEcCtD
Hyoscyamine—Rash—Doxorubicin—hematologic cancer	4.66e-05	5.41e-05	CcSEcCtD
Hyoscyamine—Dermatitis—Doxorubicin—hematologic cancer	4.66e-05	5.4e-05	CcSEcCtD
Hyoscyamine—Headache—Doxorubicin—hematologic cancer	4.63e-05	5.37e-05	CcSEcCtD
Hyoscyamine—Nausea—Doxorubicin—hematologic cancer	4.39e-05	5.09e-05	CcSEcCtD
Hyoscyamine—CHRM2—Signaling Pathways—FGF1—hematologic cancer	2.18e-05	0.000159	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—CSF2—hematologic cancer	2.18e-05	0.000159	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—FOXO1—hematologic cancer	2.17e-05	0.000159	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—MAP2K1—hematologic cancer	2.17e-05	0.000159	CbGpPWpGaD
Hyoscyamine—CHRM1—GPCR downstream signaling—IL2—hematologic cancer	2.17e-05	0.000159	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PDGFRB—hematologic cancer	2.17e-05	0.000158	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—FOXO1—hematologic cancer	2.17e-05	0.000158	CbGpPWpGaD
Hyoscyamine—CHRM3—GPCR downstream signaling—IL2—hematologic cancer	2.17e-05	0.000158	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PDGFRB—hematologic cancer	2.16e-05	0.000158	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—PIK3CD—hematologic cancer	2.16e-05	0.000158	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling by GPCR—PIK3CB—hematologic cancer	2.15e-05	0.000157	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—FOXO1—hematologic cancer	2.15e-05	0.000157	CbGpPWpGaD
Hyoscyamine—CHRM2—GPCR downstream signaling—IL2—hematologic cancer	2.14e-05	0.000156	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PDGFRB—hematologic cancer	2.14e-05	0.000156	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling by GPCR—PIK3CB—hematologic cancer	2.14e-05	0.000156	CbGpPWpGaD
Hyoscyamine—CHRM4—GPCR downstream signaling—PIK3CA—hematologic cancer	2.14e-05	0.000156	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PDGFRA—hematologic cancer	2.14e-05	0.000156	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PDGFRA—hematologic cancer	2.13e-05	0.000155	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PRKCG—hematologic cancer	2.13e-05	0.000155	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—JAK1—hematologic cancer	2.13e-05	0.000155	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—JAK1—hematologic cancer	2.12e-05	0.000155	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PRKCG—hematologic cancer	2.12e-05	0.000155	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling by GPCR—PIK3CB—hematologic cancer	2.12e-05	0.000155	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling by GPCR—KRAS—hematologic cancer	2.11e-05	0.000154	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PDGFRA—hematologic cancer	2.11e-05	0.000154	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—JAK1—hematologic cancer	2.1e-05	0.000153	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PRKCG—hematologic cancer	2.1e-05	0.000153	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—FGF2—hematologic cancer	2.07e-05	0.000151	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—PIK3R1—hematologic cancer	2.04e-05	0.000149	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—IL2RA—hematologic cancer	1.99e-05	0.000145	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—JAK2—hematologic cancer	1.98e-05	0.000145	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—IL2RA—hematologic cancer	1.98e-05	0.000145	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—PIK3CG—hematologic cancer	1.97e-05	0.000144	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling by GPCR—IL2—hematologic cancer	1.97e-05	0.000144	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling by GPCR—IL2—hematologic cancer	1.97e-05	0.000144	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—TERT—hematologic cancer	1.97e-05	0.000143	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—IL2RA—hematologic cancer	1.96e-05	0.000143	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—TERT—hematologic cancer	1.96e-05	0.000143	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling by GPCR—IL2—hematologic cancer	1.95e-05	0.000142	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling by GPCR—PIK3CA—hematologic cancer	1.94e-05	0.000142	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—TERT—hematologic cancer	1.94e-05	0.000142	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—MDM2—hematologic cancer	1.93e-05	0.000141	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PDGFB—hematologic cancer	1.92e-05	0.00014	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PDGFB—hematologic cancer	1.91e-05	0.00014	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PDGFB—hematologic cancer	1.89e-05	0.000138	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—MTOR—hematologic cancer	1.88e-05	0.000137	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—PIK3CB—hematologic cancer	1.88e-05	0.000137	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—TSC2—hematologic cancer	1.88e-05	0.000137	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—TSC2—hematologic cancer	1.87e-05	0.000136	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—TSC2—hematologic cancer	1.85e-05	0.000135	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—CREBBP—hematologic cancer	1.83e-05	0.000134	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	1.8e-05	0.000132	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	1.8e-05	0.000131	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling by GPCR—HRAS—hematologic cancer	1.8e-05	0.000131	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	1.79e-05	0.00013	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	1.78e-05	0.00013	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	1.78e-05	0.00013	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—CDKN1B—hematologic cancer	1.77e-05	0.000129	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	1.76e-05	0.000129	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—ESR1—hematologic cancer	1.75e-05	0.000128	CbGpPWpGaD
Hyoscyamine—CHRM4—GPCR downstream signaling—AKT1—hematologic cancer	1.75e-05	0.000127	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—ESR1—hematologic cancer	1.75e-05	0.000127	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—PIK3CD—hematologic cancer	1.74e-05	0.000127	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—CASP3—hematologic cancer	1.73e-05	0.000126	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—FN1—hematologic cancer	1.73e-05	0.000126	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—ESR1—hematologic cancer	1.73e-05	0.000126	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—IL2—hematologic cancer	1.73e-05	0.000126	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—FN1—hematologic cancer	1.72e-05	0.000126	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling by GPCR—IL6—hematologic cancer	1.72e-05	0.000126	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—ALB—hematologic cancer	1.71e-05	0.000125	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—BAD—hematologic cancer	1.71e-05	0.000125	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	1.71e-05	0.000125	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—FN1—hematologic cancer	1.71e-05	0.000125	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	1.7e-05	0.000124	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—BAD—hematologic cancer	1.7e-05	0.000124	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	1.69e-05	0.000124	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	1.69e-05	0.000123	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—BAD—hematologic cancer	1.69e-05	0.000123	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	1.69e-05	0.000123	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—CCND1—hematologic cancer	1.68e-05	0.000123	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—JUN—hematologic cancer	1.68e-05	0.000123	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	1.67e-05	0.000122	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—CD80—hematologic cancer	1.66e-05	0.000121	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	1.66e-05	0.000121	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—KIT—hematologic cancer	1.66e-05	0.000121	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	1.66e-05	0.000121	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—CD80—hematologic cancer	1.65e-05	0.000121	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—KIT—hematologic cancer	1.65e-05	0.00012	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	1.65e-05	0.00012	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	1.65e-05	0.00012	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—PIK3R1—hematologic cancer	1.64e-05	0.00012	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—CD80—hematologic cancer	1.64e-05	0.00012	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	1.63e-05	0.000119	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—KIT—hematologic cancer	1.63e-05	0.000119	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	1.63e-05	0.000119	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—CDKN1A—hematologic cancer	1.63e-05	0.000119	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	1.63e-05	0.000119	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—PTEN—hematologic cancer	1.63e-05	0.000119	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	1.62e-05	0.000118	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	1.61e-05	0.000117	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—MAPK8—hematologic cancer	1.59e-05	0.000116	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling by GPCR—AKT1—hematologic cancer	1.59e-05	0.000116	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	1.59e-05	0.000116	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	1.58e-05	0.000115	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—CREB1—hematologic cancer	1.58e-05	0.000115	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—CREB1—hematologic cancer	1.57e-05	0.000115	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	1.57e-05	0.000114	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—BRAF—hematologic cancer	1.56e-05	0.000114	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—CREB1—hematologic cancer	1.56e-05	0.000114	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—BRAF—hematologic cancer	1.55e-05	0.000113	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—EP300—hematologic cancer	1.55e-05	0.000113	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—CCL2—hematologic cancer	1.54e-05	0.000113	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—IL6R—hematologic cancer	1.54e-05	0.000112	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—CCL2—hematologic cancer	1.54e-05	0.000112	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—BRAF—hematologic cancer	1.54e-05	0.000112	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	1.54e-05	0.000112	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—IL6R—hematologic cancer	1.53e-05	0.000112	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	1.53e-05	0.000112	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—CCL2—hematologic cancer	1.52e-05	0.000111	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—IL6R—hematologic cancer	1.52e-05	0.000111	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	1.52e-05	0.000111	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—PIK3CB—hematologic cancer	1.51e-05	0.00011	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—SRC—hematologic cancer	1.51e-05	0.00011	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—VEGFA—hematologic cancer	1.47e-05	0.000107	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	1.47e-05	0.000107	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	1.46e-05	0.000107	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	1.46e-05	0.000106	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—STAT3—hematologic cancer	1.45e-05	0.000106	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	1.45e-05	0.000106	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—NRAS—hematologic cancer	1.45e-05	0.000106	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	1.45e-05	0.000106	CbGpPWpGaD
Hyoscyamine—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.44e-05	0.000105	CbGpPWpGaD
Hyoscyamine—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	1.44e-05	0.000105	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	1.44e-05	0.000105	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	1.43e-05	0.000104	CbGpPWpGaD
Hyoscyamine—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.42e-05	0.000104	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	1.42e-05	0.000104	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	1.41e-05	0.000103	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—FGF2—hematologic cancer	1.39e-05	0.000102	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—MAPK3—hematologic cancer	1.39e-05	0.000101	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—FGF2—hematologic cancer	1.39e-05	0.000101	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—FGF2—hematologic cancer	1.38e-05	0.0001	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	1.37e-05	0.0001	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	1.37e-05	0.0001	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	1.36e-05	9.9e-05	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—MYC—hematologic cancer	1.35e-05	9.86e-05	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—TGFB1—hematologic cancer	1.35e-05	9.84e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—JAK2—hematologic cancer	1.34e-05	9.75e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—JAK2—hematologic cancer	1.33e-05	9.72e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—JAK2—hematologic cancer	1.32e-05	9.63e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	1.31e-05	9.56e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—PTEN—hematologic cancer	1.31e-05	9.54e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	1.31e-05	9.53e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—MDM2—hematologic cancer	1.3e-05	9.52e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—MDM2—hematologic cancer	1.3e-05	9.49e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	1.29e-05	9.43e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—MDM2—hematologic cancer	1.29e-05	9.4e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—MTOR—hematologic cancer	1.27e-05	9.26e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	1.27e-05	9.26e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—MTOR—hematologic cancer	1.26e-05	9.23e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	1.26e-05	9.23e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—MTOR—hematologic cancer	1.25e-05	9.14e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	1.25e-05	9.14e-05	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—KRAS—hematologic cancer	1.25e-05	9.11e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—EP300—hematologic cancer	1.25e-05	9.1e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	1.21e-05	8.84e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	1.21e-05	8.81e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	1.2e-05	8.73e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	1.19e-05	8.69e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	1.19e-05	8.66e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	1.18e-05	8.6e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	1.18e-05	8.58e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	1.17e-05	8.57e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—CASP3—hematologic cancer	1.17e-05	8.52e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—IL2—hematologic cancer	1.17e-05	8.5e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—CASP3—hematologic cancer	1.16e-05	8.49e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	1.16e-05	8.49e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—IL2—hematologic cancer	1.16e-05	8.48e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling by GPCR—IL6—hematologic cancer	1.16e-05	8.46e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling by GPCR—IL6—hematologic cancer	1.16e-05	8.44e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—CASP3—hematologic cancer	1.15e-05	8.41e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—IL2—hematologic cancer	1.15e-05	8.4e-05	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	1.15e-05	8.37e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling by GPCR—IL6—hematologic cancer	1.14e-05	8.35e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—CCND1—hematologic cancer	1.14e-05	8.29e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—JUN—hematologic cancer	1.13e-05	8.27e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—CCND1—hematologic cancer	1.13e-05	8.26e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—JUN—hematologic cancer	1.13e-05	8.25e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—CCND1—hematologic cancer	1.12e-05	8.18e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—JUN—hematologic cancer	1.12e-05	8.17e-05	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—TP53—hematologic cancer	1.11e-05	8.1e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	1.1e-05	8.02e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PTEN—hematologic cancer	1.1e-05	8e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	1.1e-05	7.99e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PTEN—hematologic cancer	1.09e-05	7.98e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	1.08e-05	7.92e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PTEN—hematologic cancer	1.08e-05	7.9e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	1.07e-05	7.83e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	1.07e-05	7.81e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	1.07e-05	7.8e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	1.07e-05	7.78e-05	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—HRAS—hematologic cancer	1.06e-05	7.75e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	1.06e-05	7.73e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	1.06e-05	7.71e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—EP300—hematologic cancer	1.05e-05	7.63e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—EP300—hematologic cancer	1.04e-05	7.61e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—EP300—hematologic cancer	1.03e-05	7.53e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—SRC—hematologic cancer	1.02e-05	7.42e-05	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—IL6—hematologic cancer	1.02e-05	7.41e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—SRC—hematologic cancer	1.01e-05	7.4e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—SRC—hematologic cancer	1e-05	7.33e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	9.9e-06	7.23e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	9.87e-06	7.2e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—STAT3—hematologic cancer	9.81e-06	7.16e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—NRAS—hematologic cancer	9.78e-06	7.14e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	9.78e-06	7.13e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—STAT3—hematologic cancer	9.77e-06	7.13e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—NRAS—hematologic cancer	9.75e-06	7.12e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—STAT3—hematologic cancer	9.68e-06	7.06e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—NRAS—hematologic cancer	9.66e-06	7.05e-05	CbGpPWpGaD
Hyoscyamine—CHRM4—Signaling Pathways—AKT1—hematologic cancer	9.37e-06	6.84e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	9.37e-06	6.84e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	9.34e-06	6.82e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	9.25e-06	6.75e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—PIK3CA—hematologic cancer	9.22e-06	6.73e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—MYC—hematologic cancer	9.11e-06	6.65e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	9.09e-06	6.63e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—MYC—hematologic cancer	9.08e-06	6.63e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	9.06e-06	6.61e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—MYC—hematologic cancer	8.99e-06	6.56e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	8.97e-06	6.55e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—KRAS—hematologic cancer	8.42e-06	6.14e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—KRAS—hematologic cancer	8.39e-06	6.13e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—KRAS—hematologic cancer	8.31e-06	6.07e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	7.74e-06	5.65e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	7.71e-06	5.63e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	7.64e-06	5.57e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Metabolism—AKT1—hematologic cancer	7.53e-06	5.5e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—TP53—hematologic cancer	7.48e-06	5.46e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—TP53—hematologic cancer	7.46e-06	5.44e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—TP53—hematologic cancer	7.39e-06	5.39e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—HRAS—hematologic cancer	7.16e-06	5.22e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—HRAS—hematologic cancer	7.13e-06	5.21e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—HRAS—hematologic cancer	7.06e-06	5.16e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—IL6—hematologic cancer	6.85e-06	5e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—IL6—hematologic cancer	6.83e-06	4.98e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—IL6—hematologic cancer	6.76e-06	4.93e-05	CbGpPWpGaD
Hyoscyamine—CHRM1—Signaling Pathways—AKT1—hematologic cancer	6.32e-06	4.61e-05	CbGpPWpGaD
Hyoscyamine—CHRM3—Signaling Pathways—AKT1—hematologic cancer	6.3e-06	4.6e-05	CbGpPWpGaD
Hyoscyamine—CHRM2—Signaling Pathways—AKT1—hematologic cancer	6.24e-06	4.55e-05	CbGpPWpGaD
